Cognitive Markers in Prodromal MS

Part of paid clinical trials in New York, New York.

Sponsor
NYU Langone Health
Study ID
NCT05543915
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
23 Years - 59 Years
Healthy Volunteers
Not accepted

Interventions

  • Active tDCS — DEVICE
    The tDCS-MRI scan will last approximately one hour. The first 20 minutes of the MRI will not include tDCS stimulation. After 20 minutes, the tDCS device will ramp up to 2.0mA and deliver 2.0mA for 20 minutes. Then the tDCS will ramp down (30 seconds) and the final 20 minutes will be without stimulation.

Study Details

The focus of this work is the evaluation of a measure of cognitive functioning- intra-individual variability (IIV) - derived from a computer-based continuous reaction time (RT) task (Cogstate) as an early marker of prodromal MS.

Key Dates

Start date
Feb 9, 2022
Status verified
Jun 2025
Primary completion
Jun 20, 2024
Completion
Jun 20, 2024

Study Design

Enrollment
60 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING

Arms

  • Experimental: Group with tDCS-MRI
    Participants will have a cognitive assessment, an optional gait assessment, and a 1-hour MRI brain scan combined with 20 minutes of simultaneous tDCS. Participants may also complete the MRI on a separate visit.
  • No Intervention: Group without tDCS- MRI
    Participants will have include a cognitive assessment and an optional gait assessment

Primary Outcome Measure

Cerebral Metabolic Rate of Oxygen (CMRO2) [ Time Frame: Day 1 (Visit 1 - approximately 4 minutes) ]

Locations (1)

FacilityCityStateZIPSite coordinators
NYU Langone HealthNew YorkNew York10016-

Find similar trials in New York, NY

By condition
Multiple sclerosis
By specialty
NeurologyBrain disordersAutoimmune disease
By research site
NYU Langone Health· New York, NY

Related Studies